Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich.
- 1 July 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
- Vol. 10 (4) , 577-581
- https://doi.org/10.1161/01.atv.10.4.577
Abstract
It has recently been suggested that a substitution of glutamine for arginine at residue 3500 of apolipoprotein (apo) B-100 causes familial defective apo B-100 (FDB), an autosomal, dominantly inherited disorder, which leads to increased serum cholesterol levels. From a sample of 243 patients from Munich with type IIa hyperlipoproteinemia (HL), we have identified eight individuals with the apo B-100 arginine(3500)----glutamine mutation. In a group of 57 subjects with defective low density lipoprotein receptor (LDLR), no mutant apo B alleles were detected. The frequency of FDB in patients with type IIa HL was estimated to be 3%. In the kindreds of three of the probands, 10 additional carriers of the apo B mutation were identified. Clinical and biochemical data reveal a striking similarity between patients with FDB and those with a defect in the LDLR gene. Our data support previous findings that FDB is a serious disorder causing premature atherosclerosis.This publication has 15 references indexed in Scilit:
- Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten casesAtherosclerosis, 1990
- Four DNA polymorphisms in the LDL-receptor gene and their use in diagnosis of familial hypercholesterolemiaHuman Genetics, 1989
- Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins.Proceedings of the National Academy of Sciences, 1988
- Multiple crm- mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions.Journal of Clinical Investigation, 1988
- Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.Proceedings of the National Academy of Sciences, 1987
- Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hypelipidaemic individualsAtherosclerosis, 1987
- In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.Journal of Clinical Investigation, 1986
- Hyperlipidemia in Coronary Heart Disease I. LIPID LEVELS IN 500 SURVIVORS OF MYOCARDIAL INFARCTIONJournal of Clinical Investigation, 1973
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955